In 2021, transcriptomic profiling of a subset of patients enrolled in the CHAARTED clinical trial [40] revealed that mHNPC exhibits lower AR activity than non-metastatic PCa at diagnosis and is enriched in basal or luminal B subtypes according to the PAM50 (prediction analysis of microarray 50) classifier [40]. The gene discussed is AR; the disease is posterior cortical atrophy.